pharma · Asthma · Respiratory Syncytial Virus Infections
GSK Glaxo Smith
GlaxoSmithKline
GSK Glaxo Smith clinical programs — 205 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
- Employees
- 30
- Programs
- 205
- Drugs
- 194
- Patents
- 0
GSK Glaxo Smith projects
205 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.
GSK Glaxo Smith has 205 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Rotarix™
GlaxoSmithKline
Infections, Rotavirus
1 trial -
SB497115
GlaxoSmithKline
Purpura, Thrombocytopaenic, Idiopathic
1 trial -
SB497115
GlaxoSmithKline
Thrombocytopaenia
1 trial -
SERETIDE Rotacaps
GlaxoSmithKline
Asthma
1 trial -
SRA-MMB-4365/219627
GlaxoSmithKline
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
1 trial -
Solabegron
GlaxoSmithKline
Overactive Bladder
1 trial -
albiglutide
GlaxoSmithKline
Diabetes Mellitus, Type 2
1 trial -
dabrafenib
GlaxoSmithKline
Solid Tumours
1 trial -
meningococcal ACWY (vaccine)
GlaxoSmithKline
Infections, Meningococcal
1 trial -
pazopanib (GW786034)
GlaxoSmithKline
Neoplasms, Uterine Cervix
1 trial -
pazopanib (GW786034) 400 mg
GlaxoSmithKline
Neoplasms, Breast
1 trial -
sterile saline solution (0.9% w/v solution of NaCl in water).
GlaxoSmithKline
Urinary Tract Infections
1 trial -
208850
GlaxoSmithKline
Neoplasms
1 trial -
209626 (DreaMM 12)
GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma
1 trial -
209627(DREAMM 13)
GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma
1 trial -
209664
GlaxoSmithKline
Multiple Myeloma
1 trial -
213406
GlaxoSmithKline
Solid Tumours
1 trial -
217228
GlaxoSmithKline
Neoplasms
1 trial -
219728
GlaxoSmithKline
Healthy volunteers
1 trial -
219729
GlaxoSmithKline
Mild Asthma
1 trial -
220104
GlaxoSmithKline
Tuberculosis
1 trial -
221362
GlaxoSmithKline
Kidney Disease
1 trial -
221377
GlaxoSmithKline
Autosomal Dominant Polycystic Kidney Disease
1 trial -
221458
GlaxoSmithKline
Systemic Lupus Erythematosus
1 trial -
221531
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
1 trial -
221615
GlaxoSmithKline
Systemic Lupus Erythematosus
1 trial -
222110
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
222261
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
222778
GlaxoSmithKline
Urinary Tract Infections
1 trial -
300134
GlaxoSmithKline
Systemic Lupus Erythematosus
1 trial -
300163
GlaxoSmithKline
Neoplasms
1 trial -
50mg Ezogabine/retigabine
GlaxoSmithKline
Epilepsy
1 trial -
A Phase 1 study of GSK5764227 in participants with advanced solid tumors
GlaxoSmithKline
Neoplasms
1 trial -
Chloroquine
GlaxoSmithKline
Malaria
1 trial -
Daprodustat 2 mg tablet
GlaxoSmithKline
Anaemia
1 trial -
GSK2269557 ELLIPTA DPI
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
1 trial -
GSK2879552
GlaxoSmithKline
Leukaemia, Myelocytic, Acute
1 trial -
GSK525762
GlaxoSmithKline
Solid Tumours
1 trial -
GSK5533524
GlaxoSmithKline
Neoplasms
1 trial -
Lamivudine
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
New formulation
GlaxoSmithKline
Herpes Labialis
1 trial -
Pazopanib
GlaxoSmithKline
Neoplasms, Colorectal
1 trial -
Poliorix
GlaxoSmithKline
Poliomyelitis
1 trial -
Prednisolone
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
1 trial -
SB-659032
GlaxoSmithKline
Atherosclerosis
1 trial -
Test Montelukast
GlaxoSmithKline
Respiratory Disorders
1 trial -
219815
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
219871
GlaxoSmithKline
severe asthma
1 trial
Frequently asked questions
How many clinical projects does GSK Glaxo Smith have?
205 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.